Friday, August 22nd, 2025, 6:30 AM - 4 PM, Samis Education Center, 1200 Children's Ave, Oklahoma City, OK
The Symposium will provide a comprehensive and up-to-date review of the most significant advances in urologic care, featuring distinguished faculty from the OU College of Medicine and invited experts. Topics will cover a range of clinical and emerging areas, including the management of recurrent prostate cancer after radiation therapy, new approaches in ablative therapy, and advancements in radiation therapy for localized prostate cancer. Attendees will also engage in a panel discussion on prostate cancer, as well as emerging intravesical therapies for NMIBC, invasive bladder cancer updates, and bladder cancer case reviews. Key presentations will focus on adjuvant therapy for high-risk renal cell carcinoma, the role of surgery in advanced renal cell carcinoma, and novel treatments such as Cretostimogene grenadenorepvec for high-risk BCGu NMIBC.
In the afternoon, the agenda shifts to important updates in clinical practice, including the 2024 AUA OAB guideline and the management of Peyronie’s disease. Perioperative considerations in urethral stricture will also be addressed, followed by a panel discussion on female pelvic cases. Additional topics will feature pediatric urology updates, and a unique session with resident case presentations.
Urologists, Primary Care Physicians, Specialty Physicians, Oncologists, Radiation Oncologists, Related Physician Assistants, Nurses, Nurse Practitioners, Navigators, and other Administrative Staff Supporting Oncology Programs.
Mark D. Tyson, II, MD, MPH
Associate Professor of Urology & Vice chair for research, Department of Urology, Mayo Clinic Arizona
Michelle E. Van Kuiken, MD
Assistant Professor of Urology & Associate Program Director, UCSF Urology Graduate Medical Education
"Implications of the 2024 AUA OAB Guideline Update; Applications for clinical practice"
6:30 AM
BREAKFAST & EXHIBITS
7:35 AM
Introduction & Welcome
Dr. Stratton & Cookson
7:45 AM
Management of Recurrence of Prostate Cancer After Radiation Therapy
Dr. Cookson
8:00 AM
Update on Ablative Therapy for Localized Prostate Cancer
Dr. Stratton
8:15 AM
Radiation Therapy for Localized Prostate Cancer: What’s New and What’s Coming
Dr. Gunter
8:30 AM
Panel Discussion: Prostate Cancer
Moderator: Dr. Stratton Panelists: Heinlen, McIntosh, Gunter, Ramadan
9:00 AM
Overview of Emerging Intravesical Therapy options for NMIBC
Dr. Mark Tyson
9:30 AM
Updates in BCG Unresponsive Bladder Cancer
Dr. Patel
9:45 AM
What’s new in Invasive Bladder Cancer
Dr. Ayanambakkam
10:00 AM
Panel Discussion: Bladder Cancer Cases
Moderator: Dr. Patel
Panelists: Dr. Tyson, Dr. A,
Dr. Cross
10:30 AM
BREAK & EXHIBITS
11:00 AM
Adjuvant Therapy for High-Risk ccRCC – breaking down the data
Dr. McIntosh
11:15 AM
Role of Surgery for Advanced and Metastatic Renal Cell Carcinoma
11:30 AM
Cretostimogene grenadenorepvec for high risk BCGu NMIBC
12:00 PM
LUNCH & EXHIBITS
12:55 PM
Overview of Afternoon and Introductions
Dr. Furr
1:00 PM
Implications of the 2024 AUA OAB Guideline Update; Applications for clinical practice
Dr. Michelle Van Kuiken
1:30 PM
Peyronie’s Disease: Updates in Clinical Management
Dr. Doolittle
1:45 PM
Perioperative Considerations in Urethral Stricture
2:00 PM
Panel Discussion: Female Pelvic Cases
Moderator: Slobodov Panelists: Drs. Van Kuiken, Cunningham, Arielle Allen
2:30 PM
Female Stress Urinary Incontinence – where are we in 2025?
Dr. Van Kuiken
3:00 PM
Pediatric Urology Update
Dr. Rensing
3:15 PM
Resident Case Presentations: Four 8 min presentations T-Leon Howard style, prize for winner
Abdul Qadar, PGY5, Jaisa Kauffman, PGY4, Amber Bauer, PGY3, Ben Cooper, PGY3
3:45:00 PM - 4:00 PM
Closing Remarks Q&A
The University of Oklahoma Health Science
2025 Oklahoma Urologic Symposium August 22, 2025 Oklahoma City, OK
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and The University of Oklahoma Health Science Center. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits TM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP.
PAs may claim a maximum of 6.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.